SEC Form 4 · accession 0001662252-16-000276
Xenetic Biosciences, Inc. · XBIO
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Jeffrey F Eisenberg
Officer — COO · Director
Period of report
Dec 2, 2016
Accepted (ET)
Dec 6, 2016 · 4:07 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001534525
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock OptionsF1 | $3.40 | Dec 2, 2016 | A | 4,700 | A | Dec 2, 2016 | Dec 1, 2026 | Common Stock | 4,700 | 4,700 | D |
| Stock Options | $3.40 | Dec 2, 2016 | A | 75,100 | A | Dec 2, 2017 | Dec 1, 2026 | Common Stock | 75,100 | 79,800 | D |
| Stock Options | $3.40 | Dec 2, 2016 | A | 75,100 | A | Dec 2, 2018 | Dec 1, 2026 | Common Stock | 75,100 | 154,900 | D |
| Stock Options | $3.40 | Dec 2, 2016 | A | 75,100 | A | Dec 2, 2019 | Dec 1, 2026 | Common Stock | 75,100 | 230,000 | D |
Explanation of responses
- F1On December 2, 2016 the Issuer entered into an Employment Agreement with Mr. Eisenberg. Under the terms of the Employment Agreement, Mr. Eisenberg has the right to purchase 230,000 shares of common stock of the Issuer (the "Option") under the Issuer's Equity Incentive Plan, effective January 23, 2014 (the "Plan") at an exercise price equal to the fair market value of the Company's common stock on the grant date. 4,700 shares were granted pursuant to the Option were deemed vested immediately. The Options expire December 1, 2026.